The Best Small-Cap Stocks to Buy Now
Biotech, real estate and software dominate the list of Wall Street's best small-cap stocks to buy.
The final quarter of 2025 and first quarter of the new year could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps have underperformed during the current bull market. After all, small caps as an asset class have been a dud. They've struggled to keep up as mega-cap stocks pushed the broader market to record highs.
To recap: the broader S&P 500 is up more than 80% since the bull market's onset three years ago. The tech-heavy Nasdaq Composite more than doubled over the same span. Hurt partly by its price-weighted construction, the blue-chip Dow Jones Industrial Average gained just 55%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) have been fueling much of the market's gains. And so small caps – which tend to be more sensitive to the economic cycle, tariffs and interest rates – are lagging badly.
Indeed, the small-cap benchmark Russell 2000 Index is up just 41% over the past three years.
If there is a sliver of a silver lining to the Russell 2000's chronic underperformance, it's that small cap valuations look dirt cheap.
"The broadening of profits growth is finally extending into small caps," notes Jill Carey Hall, an equity and quant strategist at BofA Securities. "Small caps continue to trade at about a 30% historical discount to large caps, implying likelihood of outperformance over the long-term. We remain constructive on small caps for now."
And with the Federal Reserve expected to enact several cuts to the federal funds rate in the coming quarters, small caps should have at least one catalyst behind them.
Our methodology for finding the best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell.
Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 12 Strong Buy recommendations to ensure adequate analyst coverage and sample size. Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data to find the best stocks to buy.
Our screen of the Street's top small-cap stocks served up a list dominated by the health care sector, mostly pharmaceutical and biotechnology companies.
That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a gaming stock and real estate investment trust (REIT), for instance – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Analysts' consensus recommendation score | Subsector | Analysts' consensus recommendation |
|---|---|---|---|
Spyre Therapeutics (SYRE) | 1.14 | Biotechnology | Strong Buy |
Denali Therapeutics (DNLI) | 1.16 | Biotechnology | Strong Buy |
Waystar Holding (WAY) | 1.19 | Health Care Technology | Strong Buy |
Xenon Pharmaceuticals (XENE) | 1.21 | Biotechnology | Strong Buy |
Genius Sports (GENI) | 1.22 | Casinos & Gaming | Strong Buy |
Janux Therapeutics (JANX) | 1.22 | Biotechnology | Strong Buy |
Axsome Therapeutics (AXSM) | 1.25 | Pharmaceuticals | Strong Buy |
Wave Life Sciences (WVE) | 1.27 | Pharmaceuticals | Strong Buy |
Kymera Therapeutics (KYMR) | 1.27 | Biotechnology | Strong Buy |
Riot Platforms (RIOT) | 1.28 | Application Software | Strong Buy |
Avidity Biosciences (RNA) | 1.28 | Biotechnology | Strong Buy |
Braze (BRZE) | 1.30 | Application Software | Strong Buy |
Biohaven (BHVN) | 1.33 | Biotechnology | Strong Buy |
Guardant Health (GH) | 1.35 | Health Care Services | Strong Buy |
BridgeBio Pharma (BBIO) | 1.37 | Biotechnology | Strong Buy |
Essential Properties Realty Trust (EPRT) | 1.37 | Diversified REITs | Strong Buy |
Arcellx (ACLX) | 1.39 | Biotechnology | Strong Buy |
Privia Health Group (PRVA) | 1.40 | Health Care Services | Strong Buy |
IDEAYA Biosciences (IDYA) | 1.42 | Biotechnology | Strong Buy |
NetSTREIT (NTST) | 1.50 | Retail REITs | Strong Buy |
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
Stocks See First Back-to-Back Losses of 2026: Stock Market TodayRising geopolitical worries and a continued sell off in financial stocks kept pressure on the main indexes on Wednesday.
-
Countries That Will Pay You to Move: Cash Grants, Incentives and What to KnowExplore real relocation incentives — from cash grants and tax breaks to startup funding — that make moving abroad or to smaller towns more affordable and rewarding.
-
Mortgage Protection Insurance: What It Covers and When It Makes SenseHow mortgage protection insurance works, what it costs, and when it’s actually useful in a financial plan.
-
Stocks See First Back-to-Back Losses of 2026: Stock Market TodayRising geopolitical worries and a continued sell off in financial stocks kept pressure on the main indexes on Wednesday.
-
I'm a Real Estate Expert: 2026 Marks a Seismic Shift in Tax Rules, and Investors Could Reap Millions in RewardsThree major tax strategies will align in 2026, creating unique opportunities for real estate investors to significantly grow their wealth. Here's how it works.
-
When Can Tax Planning Be an Act of Love? This Family Found OutHow can you give stock worth millions to a loved one without giving them a huge capital gains tax bill? This family's financial adviser provided the answer.
-
Forget Job Interviews: Employers Will Find the Best Person for the Job in an Escape Room (This Former CEO Explains Why)Escape rooms can give employers a better indication of job candidates' strengths than a standard interview. Here's how your company can get on board.
-
Visa Stamps the Dow's 398-Point Slide: Stock Market TodayIt's as clear as ever that President Donald Trump and his administration can't (or won't) keep their hands off financial markets.
-
The December CPI Report Is Out. Here's What It Means for the Fed's Next MoveThe December CPI report came in lighter than expected, but housing costs remain an overhang.
-
The Paradox Between Money and Wealth: How Do You Find the Balance?Wealth reflects a life organized around relationships, health, contribution and time — qualities that compound differently than money in a mutual fund.
-
Billed 12 Hours for a Few Seconds of Work: How AI Is Helping Law Firms Overcharge ClientsThe ability of AI to reduce the time required for certain legal tasks is exposing the legal profession's reliance on the billable hour.